Estrella Immunopharma logo
Estrella Immunopharma
ESLA | NASDAQ
Chart Builder DCF Calculator
$0.38
-$0.13 (-26.07%)
At close: Nov 16, 2026, 4:00 PM ET
$0.41
+$0.03 (+7.37%)
After-hours: Nov 16, 2026, 7:47 PM ET

Estrella Immunopharma Company Profile

Company profile explained

Company Profile

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Key Executives

Name Position
Cheng Liu Chief Executive Officer, President & Director
Jiandong Xu Chief Financial Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 26, 2026 4 Filing
Aug 25, 2026 4 Filing
Aug 21, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 10-Q Quarterly Report
Jun 30, 2026 8-K Current Report
May 27, 2026 DEF 14A Filing
May 18, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Estrella Immunopharma
Estrella Immunopharma logo
Country United States
IPO Date Sep 14, 2021
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Cheng Liu

Contact Details

5858 Horton Street EmeryVille, California 94608 United States

Stock Details

Ticker Symbol ESLA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001844417
CUSIP Number 297584104
ISIN Number US2975841048
SIC Code 6770

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.